Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2012
This article has no abstract
Epistemonikos ID: bfd282d12802a4b9ca67a1993dbf1ff86db15b81
First added on: Feb 05, 2025